Randomized, placebo-controlled trial of injectable extended-release naltrexone and injectable extended-release buprenorphine for cocaine use disorder (CURB-2): Study rationale and design
Contemporary Clinical Trials · 2025
DOI: 10.1016/j.cct.2025.107954 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2025. Verfasst von Madhukar H Trivedi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and Department of Psychiatry, University of Texas Southwestern …. Hauptthemen laut MEDLINE: Cocaine-Related Disorders, Narcotic Antagonists, Naltrexone, Buprenorphine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse, National Institute on Drug Abuse Clinical Trials Network.
Abstract (Originalsprache)
BACKGROUND: Cocaine remains the most abused stimulant, causing considerable morbidity and mortality. Despite decades of research, there is no FDA-approved medication to treat cocaine use disorder (CUD). In individuals with cocaine and opioid dependence/abuse, extended-release injectable naltrexone (XR-NTX) and sublingual buprenorphine (BUP; 16 mg with naloxone; Suboxone) reduced cocaine use compared to placebo and XR-NTX in the 'Cocaine Use Reduction with Buprenorphine' (CURB; CTN-0048) study. OBJECTIVES: The CURB-2 (CTN-0109) study aims to examine whether administering XR-NTX in combination with extended-release injectable buprenorphine (XR-BUP), thus creating a "kappa antagonist," is an effective pharmacotherapy compared to placebo for the treatment of CUD. STUDY DESIGN: CURB-2 is a fully powered, phase IIb, randomized, placebo-controlled trial. Approximately 426 participants will be randomized across 12 study sites in the United States. There will be a 1-week medication induction phase, an 8-week active medication phase, and a 4-week follow-up phase. XR-NTX (Day 1, Week 3, Week 6) will be administered before XR-BUP (Day 4, Week 4). With naltrexone blocking the mu-opioid receptors, the reinforcing effects of buprenorphine will be blocked while leaving the kappa antagonist effects. DISCUSSION: If this kappa antagonist approach demonstrates efficacy in reducing urine-verified cocaine use compared to placebo, XR-NTX and XR-BUP combination therapy would be an important tool in addressing cocaine use disorder. CLINICAL TRIALS REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT05262270.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA. Electron…
- Department of Family Medicine, University of California, Los Angeles, 1800 Wilshire Blvd., Suite 1800, CA 90024, USA.
- Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA; Departme…
- The Emmes Company, LLC, 401 N Washington St #700, Rockville, MD 20850, USA.
- Center for the Clinical Trials Network (CCTN), The National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Rockville, MD, USA.
- Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA.
Förderung
- NIDA NIH HHS
- National Institute on Drug Abuse
- National Institute on Drug Abuse Clinical Trials Network
Zitieren
APA
Trivedi, M. H., Kalmin, M. M., Carmody, T., Chongsi, E. M., Ghitza, U. E., Jha, M. K., Mayes, T. L., Casey-Willingham, A., Sethuram, S., Marino, E. N., Monastirsky, M., & Shoptaw, S. J. (2025). Randomized, placebo-controlled trial of injectable extended-release naltrexone and injectable extended-release buprenorphine for cocaine use disorder (CURB-2): Study rationale and design. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2025.107954
Vancouver
Trivedi MH, Kalmin MM, Carmody T, Chongsi EM, Ghitza UE, Jha MK, et al. Randomized, placebo-controlled trial of injectable extended-release naltrexone and injectable extended-release buprenorphine for cocaine use disorder (CURB-2): Study rationale and design. Contemporary Clinical Trials. 2025. doi:10.1016/j.cct.2025.107954
BibTeX
@article{Trivedi2025,
author = {Trivedi, Madhukar H and Kalmin, Mariah M and Carmody, Thomas and Chongsi, Edward M and Ghitza, Udi E and Jha, Manish K and Mayes, Taryn L and Casey-Willingham, Angela and Sethuram, Sangita and Marino, Elise N and Monastirsky, Maria and Shoptaw, Steven J},
title = {Randomized, placebo-controlled trial of injectable extended-release naltrexone and injectable extended-release buprenorphine for cocaine use disorder (CURB-2): Study rationale and design},
journal = {Contemporary Clinical Trials},
year = {2025},
doi = {10.1016/j.cct.2025.107954}
}
EUVIMED